Regulus Therapeutics Inc. [NASDAQ: RGLS] loss -29.88% or -0.23 points to close at $0.53 with a heavy trading volume of 16590619 shares. The company report on October 13, 2021 that Regulus Therapeutics Announces Strategic Prioritization of RGLS8429, its Next-Generation Candidate for the Treatment of Autosomal Dominant Polycystic Kidney Disease.
-Company will advance RGLS8429 supported by strong preclinical data and superior pharmacologic profile as compared to first-generation RGLS4326-.
-Validating sections of IND-enabling toxicity studies for RGLS8429 have been completed, with IND submission and Phase 1 initiation expected in Q2 2022-.
It opened the trading session at $0.54, the shares rose to $0.5514 and dropped to $0.5003, the range by which the price of stock traded the whole day. The daily chart for RGLS points out that the company has recorded -61.96% loss over the past six months. However, it is still -17.78% lower than its most recent low trading price.
If we look at the average trading volume of 933.41K shares, RGLS reached to a volume of 16590619 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Regulus Therapeutics Inc. [RGLS]:
B. Riley FBR Inc. have made an estimate for Regulus Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 28, 2018. While these analysts kept the previous recommendation, Leerink Partners raised their target price to Outperform. The new note on the price target was released on January 05, 2018, representing the official price target for Regulus Therapeutics Inc. stock. Previously, the target price had yet another drop from $5 to $2.50, while Chardan Capital Markets kept a Buy rating on RGLS stock. On March 06, 2017, analysts decreased their price target for RGLS shares from 8 to 6.
The Average True Range (ATR) for Regulus Therapeutics Inc. is set at 0.06, with the Price to Sales ratio for RGLS stock in the period of the last 12 months amounting to 4.52. The Price to Book ratio for the last quarter was 1.11, with the Price to Cash per share for the same quarter was set at 0.49.
Trading performance analysis for RGLS stock
Regulus Therapeutics Inc. [RGLS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -21.68. With this latest performance, RGLS shares dropped by -26.89% in over the last four-week period, additionally sinking by -61.96% over the last 6 months – not to mention a drop of -5.50% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RGLS stock in for the last two-week period is set at 31.80, with the RSI for the last a single of trading hit 26.72, and the three-weeks RSI is set at 35.46 for Regulus Therapeutics Inc. [RGLS]. The present Moving Average for the last 50 days of trading for this stock 0.7204, while it was recorded at 0.6856 for the last single week of trading, and 1.0875 for the last 200 days.
Regulus Therapeutics Inc. [RGLS]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Regulus Therapeutics Inc. [RGLS] shares currently have an operating margin of -141.47. Regulus Therapeutics Inc.’s Net Margin is presently recorded at -157.21.
Return on Total Capital for RGLS is now -42.58, given the latest momentum, and Return on Invested Capital for the company is -68.25. Return on Equity for this stock declined to -68.33, with Return on Assets sitting at -39.48. When it comes to the capital structure of this company, Regulus Therapeutics Inc. [RGLS] has a Total Debt to Total Equity ratio set at 19.69. Additionally, RGLS Total Debt to Total Capital is recorded at 16.45, with Total Debt to Total Assets ending up at 13.63.
Reflecting on the efficiency of the workforce at the company, Regulus Therapeutics Inc. [RGLS] managed to generate an average of -$655,417 per employee. Receivables Turnover for the company is 12.17 with a Total Asset Turnover recorded at a value of 0.25.Regulus Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.60 and a Current Ratio set at 4.60.
Regulus Therapeutics Inc. [RGLS]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RGLS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Regulus Therapeutics Inc. go to 39.60%.
An analysis of insider ownership at Regulus Therapeutics Inc. [RGLS]
There are presently around $12 million, or 37.90% of RGLS stock, in the hands of institutional investors. The top three institutional holders of RGLS stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 6,451,056, which is approximately 0% of the company’s market cap and around 0.40% of the total institutional ownership; VANGUARD GROUP INC, holding 3,095,237 shares of the stock with an approximate value of $1.65 million in RGLS stocks shares; and ENDURANT CAPITAL MANAGEMENT LP, currently with $1.39 million in RGLS stock with ownership of nearly 9.725% of the company’s market capitalization.
Positions in Regulus Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 26 institutional holders increased their position in Regulus Therapeutics Inc. [NASDAQ:RGLS] by around 2,369,168 shares. Additionally, 16 investors decreased positions by around 6,892,670 shares, while 14 investors held positions by with 13,603,307 shares. The mentioned changes placed institutional holdings at 22,865,145 shares, according to the latest SEC report filing. RGLS stock had 13 new institutional investments in for a total of 853,868 shares, while 12 institutional investors sold positions of 5,937,002 shares during the same period.